Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).

Katsumata, N; Watanabe, T; Minami, H; Aogi, K; Tabei, T; Sano, M; Masuda, N; Andoh, J; Ikeda, T; Shibata, T; Takashima, S

Katsumata, N; Watanabe, T; Minami, H; Aogi, K; Tabei, T; Sano, M; Masuda, N; Andoh, J; Ikeda, T; Shibata, T; Takashima, S.

Affiliation

Katsumata N; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. nkatsuma@ncc.go.jp

Ann Oncol ; 20(7): 1210-5, 2009 Jul.

Article in En | MEDLINE | ID: mdl-19254942

Subject(s)

Antineoplastic Agents/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Breast Neoplasms/pathology; Cyclophosphamide/administration & dosage; Docetaxel; Doxorubicin/administration & dosage; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Taxoids/administration & dosage; Time Factors; Treatment Failure; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Ann Oncol Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google